Zimmer Biomet Sees Q4 Revenues Above Expectations

Shares of Zimmer Biomet Holdings were up over 1% pre-market Tuesday after the company said it expects Q4 revenues just above forecasts compiled by Capital IQ.

The provider of musculoskeletal healthcare expects Q4 revenues of $2.01 billion, up 4.1% year-over-year and slightly above the $1.97 billion consensus.

FY16 revenues are seen at $7.68 billion, up 28.1% from a year earlier and also just above the $7.64 billion average estimate. Zimmer Biomet also expects FY16 adjusted EPS to be near the upper end of the previously provided range of $7.90 to $7.95 per share, with analysts expecting full-year adjusted EPS of $7.92 per share.

Leave a Comment